Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Boston ‘Unicorn’ Intarcia Banks a Whopping $215 Million to Support Diabetes Drug Pump

Intarcia Therapeutics is well on its way to securing $600 million in financing. The company recently posted $215 million in a new round of financing and is on its way to seeking regulatory approval for its matchstick-sized diabetes therapeutic platform, ITCA-650.

Read More »

Novo plans larger study for semaglutide

Novo Nordisk’s experimental injectable diabetes drug semaglutide reduced cardiovascular risk by 26 percent, paving the way for a bigger study on the drug’s benefits.

Read More »

How Scientific Affairs Can Assist Your Team with the FDA

While acknowledging the many complexities of product development, sponsor teams should factor in these six guiding principles when planning programs for regulatory submission.

Read More »

Novavax Stayin’ Alive After Shares Crater on Flunked Phase III

Shares of Novavax plummeted more than 82 percent after the company released data that its Phase III trial for its RSV F Vaccine for older adults did not meet its goals, failing to demonstrate “vaccine efficacy.”

Read More »

Shaping the Understanding of Measurement at the Point of Care, An Expert Discussion

A roundtable of experts discuss what is the single most imperative thing marketers understand about the unique measurability and data-driven targeting that is possible within point of care.

Read More »

U.S. approves Aralez pill for heart patients

The U.S. FDA approved a pill that combines aspirin and the acid-fighting drug omeprazole to guard against gastric ulcers in patients who require daily aspirin.

Read More »

Partnership for Drug-Free Kids Announces National Launch of “Search and Rescue” Opioid Prescriber Education Campaign

Partnership for Drug-Free Kids announced the national launch of “Search and Rescue,” a prescriber education campaign that gives healthcare providers the resources they need to prescribe opioids responsibly and prevent the misuse and abuse of medicine in their practices.

Read More »

Bay Area’s Rigel Slashes 38% of Workforce; Shifts From R&D to Commercial Operation

In light of its August 30 announcement that its fostamatinib met its primary endpoints in two Phase III clinical trials, Rigel Pharmaceuticals reported that it will undergo major restructuring as it shifts from a research-and-discovery company to a commercial organization.

Read More »

Teva, Intel to develop wearables to monitor Huntington’s disease

Teva Pharmaceutical Industries Ltd. said it was collaborating with Intel Corp. to develop a wearable device to monitor patients with Huntington’s, a fatal degenerative disease.

Read More »

In the branding of Xiidra, the ii’s have it

Shire Inc. recently launched Xiidra, the first medicine indicated for the signs and symptoms of dry eye disease and the company’s first ophthalmic drug.

Read More »

AcelRx’s opioid painkiller succeeds in key study

AcelRx Pharmaceuticals Inc. said its experimental opioid painkiller was well tolerated in post-operative patients in a late-stage study.

Read More »

Eisai Company Launches Ambitious 90-Scientist Collaborative R&D Unit in Boston Area

Eisai Inc., the U.S. subsidiary of Japan’s Eisai Co. Ltd., announced that it is launching a research-and-discovery unit in the Boston area to focus on Alzheimer’s, cancer and autoimmune diseases. The new unit will be called the Eisai Andover Innovative Medicines (AiM) Institute and will be located in Andover, Mass.

Read More »

GSK shingles vaccine remains effective after four years: study

GlaxoSmithKline’s experimental vaccine to prevent the intensely painful condition known as shingles remained 90 percent effective in people over age 70 even four years after receiving the injection, according to published data.

Read More »

Aerie’s eye drug meets main goal in late-stage study; shares jump

Aerie Pharmaceuticals Inc. said its eye drug met the main goal in a late-stage study, sending the company’s shares up 71 percent in extended trading.

Read More »

Mylan CEO to testify before House panel over EpiPen pricing

Mylan NL Chief Executive Officer Heather Bresch will appear at a Sept. 21 congressional hearing over price increases for its allergy auto-injector EpiPen, the U.S. House of Representatives Oversight Committee said in a statement.

Read More »

Allergan to Acquire Vitae Pharmaceuticals

Allergan plc will acquire Vitae Pharmaceuticals Inc. for $21.00 per share, in cash, for a total transaction value of approximately $639 million.

Read More »

Shire’s Cuvitru wins FDA approval

Shire Plc said the U.S. FDA approved its treatment for patients with primary immunodeficiency, a group of genetic disorders.

Read More »

U.N. panel challenges market-based approach to drug R&D

The world cannot rely solely on free markets to deliver medicines needed by billions of people in poor countries, so governments should commit to a legally binding convention to coordinate and fund research and development. That is the conclusion of a major United Nations report, which is bound to stir fierce debate between supporters of the current market-based system of drug development and those favoring a greater role for the state.

Read More »

Asterias stem cell therapy shows promise in spinal cord paralysis: U.S. study

An experimental stem cell therapy developed by Asterias Biotherapeutics restored some movement to patients paralyzed by recent spinal cord injuries, according to interim data from a small study.

Read More »

Hungry Like a Wolf, Takeda Sets Aside $15 Billion Cash for U.S. Acquisitions

Takeda is on the prowl and looking for big game. The company has set aside $15 billion to go after U.S. pharmaceutical acquisitions in an effort to reduce its dependency on the Japanese domestic market, which has been sluggish of late, Reuters reported.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom